Press Releases April 8, 2026 08:00 PM

Latham Group, Inc. Announces First Quarter 2026 Earnings Release and Conference Call Date

Latham Group schedules Q1 2026 earnings release and conference call for May 5, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
SWIM

Latham Group, Inc., a leading designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, announced it will release its Q1 2026 financial results after the U.S. market closes on May 5, 2026, followed by a conference call to discuss the results. Investors can access the call via pre-registration or listen to a live webcast.

Latham Group, Inc. Announces First Quarter 2026 Earnings Release and Conference Call Date
SWIM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Latham Group operates primarily in the residential swimming pool sector, with 1,900 employees across 35 locations.
  • The company will release its first quarter 2026 earnings on May 5, 2026, followed by a conference call at 4:30 PM ET.
  • Accessibility for investors is emphasized with pre-registration for the call and archived webcast availability for one year.

LATHAM, N.Y., April 09, 2026 (GLOBE NEWSWIRE) -- Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it will release financial results for the first quarter 2026 on Tuesday, May 5, 2026, after the close of the U.S. market. The Company will hold a conference call to discuss the results that same day at 4:30 PM Eastern Time.

We encourage participants to pre-register for the conference call by visiting https://dpregister.com/sreg/10207783/103af06e389. Callers who pre-register will be sent a confirmation e-mail including a conference passcode and unique PIN to gain immediate access to the call. Participants may pre-register at any time, including up to and after the call start time. To ensure you are connected for the full call, please register at least 10 minutes before the start of the call.

A live audio webcast of the conference call will be available online at https://ir.lathampool.com/ under “Events & Presentations.”

Those without internet access, or unable to pre-register, may dial in by calling:

PARTICIPANT DIAL-IN (TOLL-FREE): 1-833-953-2435
PARTICIPANT INTERNATIONAL DIAL-IN: 1-412-317-5764

For those who are unable to listen to the live broadcast, an archived webcast will be available approximately two hours after the conclusion of the call, through May 5, 2027, on the Company’s investor relations website under “Events & Presentations.”

About Latham Group, Inc.

Latham Group, Inc., headquartered in Latham, NY, is the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand. Latham has a coast-to-coast operations platform consisting of approximately 1,900 employees across 35 locations.

Contact:

Lynn Morgen
Casey Kotary
ADVISIRY Partners
[email protected]
212-750-5800


Risks

  • Financial performance in Q1 2026 may differ from expectations, introducing earnings volatility.
  • Market conditions affecting the housing and construction sectors could impact demand for residential swimming pools.
  • Global geopolitical or economic uncertainties, especially in North America, Australia, and New Zealand, could influence operational results.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026